-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3771 The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation
Program: Oral and Poster Abstracts
Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III
Monday, December 7, 2015, 6:00 PM-8:00 PM
Hall A, Level 2 (Orange County Convention Center)

Musa Yilmaz, MD1*, Hagop M. Kantarjian, MD2, Farhad Ravandi, MD2, Jeffrey L. Jorgensen, MD, PhD3, Sa Wang, MD4*, Guillermo Garcia-Manero, MD5, Jorge E. Cortes, MD6, Koji Sasaki, MD2, Courtney DiNardo, MD2, Tapan Kadia, MD2, Jane Autry, RN7*, Rebecca Garris2* and Elias Jabbour2

1Department of Hematology & Oncology, Baylor College of Medicine, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX
6Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston

Introduction:  MRD positivity after induction/consolidation therapy in pts with de novo ALL has been shown to carry a very negative impact on outcome. However, the significance of MRD status in the salvage setting has not been extensively studied.

Methods:  We evaluated 130 pts with R/R B-cell ALL pts who received first (n=68), or second (n=62), salvage therapy between 2010 and 2015. Salvage therapies included single agent inotuzumab ozogamicin (INO; n=75), blinatumomab (n=20), or INO in combination with mini-hyper-CVD (n=35) [Jabbour E et al; EHA 2015]. Of the 130 pts treated, 78 (60%) responded and were assessed for MRD by six-color flow cytometry on marrow samples with a sensitivity of 0.01%. Morphologic responses were defined as follows, complete response (CR); disappearance of all disease with neutrophils ≥ 1.0 X 109/L, platelet > 100 X 109/L and blasts ≤ 5%, CRp; CR without platelet recovery, CRi; CR without platelet and/or neutrophil recovery.

Results: The clinical characteristics of the 78 responding pts with R/R ALL are summarized in Table 1. Overall, MRD negativity was achieved at response in 41 pts (53%). Among the 41 pts who responded to single agent INO (12 CR, 26 CRp, 3CRi), 17 (41%) achieved a negative MRD status.  Among the 11 pts who responded to blinatumomab (9 CR, 2Cri), 8 (73%) achieved a negative MRD status.  Among the 26 pts who responded to INO in combination with mini-HCVD (21 CR, 4 CRp, 1CRi), 16 (62%) achieved a negative MRD status. Forty-four pts received allogeneic stem cell transplantation (ASCT): of those, 21 pts were MRD negative and 23 pts were MRD positive at the time of response.  Median follow-up was 19 months (2-55). Overall, there was a trend for more durable morphologic responses in MRD negative pts compared with MRD positive pts: the median complete remission durations (CRD) were 17 months and 8 months, with a 2-year CRD rate of 47% and 28% respectively (Table 2). The median event-free survival (EFS) was 12 and 6 months, respectively; the 2-year EFS rates were 32% and 8%, respectively. Similarly, there was a trend for better overall survival (OS) with a median of 17 months and 9 months for pts with negative and positive MRD, respectively; the 2-year OS rates were 36% and 27%, respectively. No difference in outcome was reported whether pts were censored or not at the time of ASCT.

Conclusion: In pts with R/R ALL, the achievement of negative MRD in addition to the morphologic response confers an improvement, although not statistically significant, in response duration and survival. Larger number of pts with longer follow-up is needed to validate these findings.  

Table 1. Clinical Characteristics of Pts (n=78)

 

N (%)/Median [range]

Age (years)

38 [18-87]

Sex (Male)

50 (64)

Performance Status

1 [1-3]

WBC (x 109/L)

3 [0.3-38]

% PB Blasts

0 [0-83]

% BM Blasts

60 [8-97]

Cytogenetics

   Diploid

20 (26)

   t(9;22)

4 (5)

   t(4;11)

7 (9)

   Miscellaneous

39 (50)

 Not done/ Insufficient metaphases

8 (10)

Salvage

 

   Inotuzumab Ozogamicin

41 (53)

   Blinatumomab

11 (14)

   Inotuzumab Ozogamicin + mini-HCVD

26 (33)

Number of prior therapies

 

   1 prior therapy

46 (59)

   2 prior therapies

32 (41)

 

Table 2. Response Rates and Survival by MRD Status

 

MRD Negative (n=41)

MRD Positive (n=37)

p

CR

24

18

n/a

CRp

16

14

n/a

CRi

1

5

n/a

CRD, median (m)

17

8

0.63

  2-year CRD rate (%)

47

28

EFS, median (m)

12

6

0.06

  2-year EFS rate (%)

32

8

OS, median (m)

17

9

0.18

  2-year OS rate (%)

36

27

 

Disclosures: Cortes: Teva: Research Funding ; BMS: Consultancy , Research Funding ; Novartis: Consultancy , Research Funding ; BerGenBio AS: Research Funding ; Pfizer: Consultancy , Research Funding ; Ariad: Consultancy , Research Funding ; Astellas: Consultancy , Research Funding ; Ambit: Consultancy , Research Funding ; Arog: Research Funding ; Celator: Research Funding ; Jenssen: Consultancy . DiNardo: Novartis: Research Funding .

*signifies non-member of ASH